Valeant Turns Assets to Cash With $2.1 Billion in Deals

The video discusses a company's financial strategy, focusing on its $30 billion debt and asset sales worth $2 billion. It highlights the positive investor response to asset sales, including Dendreon and dermatology assets, and the challenges of future debt obligations. The company may need to sell $5 to $15 billion in assets, with potential sales of core businesses like Salix. The discussion includes valuation, bond principles, and term loans, emphasizing the need for strategic asset sales to manage debt effectively.

What is the total amount of debt that the company is sitting on?

What are the investors' perceptions regarding the recent asset sales?

What was the concern regarding the sale of the cancer asset Dendreon?

How much in asset sales have they discussed needing to achieve?

What was the outcome of the potential sale of the Salix business?